news Artificial intelligence could revolutionise glycomics datasets 9 September 2021 | By Anna Begley (Drug Target Review) Researchers have created a tool that allows glycomics datasets to be analysed using artificial intelligence for early cancer diagnoses.
news Stem-like T cells could improve immunotherapy treatments 7 September 2021 | By Anna Begley (Drug Target Review) Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
news RN7SL1 RNA shown to activate T cells to fight against cancer 6 September 2021 | By Anna Begley (Drug Target Review) A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
news High-intensity focused ultrasound therapy moves closer to the clinic 24 August 2021 | By Anna Begley (Drug Target Review) Researchers are investigating how high-intensity focused ultrasound (HIFU) can work on a cellular level to treat a range of cancers.
news Enzyme discovery could fight against cancer and viral infections 17 August 2021 | By Anna Begley (Drug Target Review) A new study has identified a vital enzyme, known as APOBEC3A, that could lead to new treatments against cancers and viral infections.
news Novel database could accelerate drug repurposing for various diseases 4 August 2021 | By Anna Begley (Drug Target Review) NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
news AKT degrader may become a new, effective treatment for many cancers 29 July 2021 | By Anna Begley (Drug Target Review) Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.
news Inhibiting PIP4K enzymes could help immune system fight cancer 27 July 2021 | By Anna Begley (Drug Target Review) Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
news Personalised organoid models may improve immunotherapy treatment 23 July 2021 | By Anna Begley (Drug Target Review) Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
news Bacterial metabolites could increase tumour therapy efficiency 22 July 2021 | By Anna Begley (Drug Target Review) Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
article Lentiviral vectors: the key to cancer treatments that CAR T-cell therapy cannot reach? 21 July 2021 | By Professor Christian Brechot (TheraVectys) Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
article Recognition of phosphohistidine-containing peptides by antibodies 16 July 2021 | By Dr Rajasree Kalagiri (Salk Institute), Professor Tony Hunter (Salk Institute) In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
news Newly designed tumour vaccine could prevent cancer recurrence 9 July 2021 | By Anna Begley (Drug Target Review) Scientists have used nanotechnology to develop personalised tumour vaccines which prevented cancer recurrence and metastasis challenges in mouse models.
news Protein activation discovery could widen access to cancer immunotherapy 8 July 2021 | By Anna Begley (Drug Target Review) The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
news Bioactivity information of one million molecules compiled 1 July 2021 | By Victoria Rees (Drug Target Review) Using deep machine learning, researchers have completed the activity profiles, from chemistry to clinical level, for one million molecules.
